Ranked #1
030 - JP Morgan and Q1-19 Expectations!
030 - JP Morgan and Q1-19 Expectations!
Hey everybody! I'm back with a new video talking about news in January from my favorite biotech companies. There was a l... Read more
2 Feb 2019
•
23mins
Ranked #2
040 - Biogen faces another headwind with Zolgensma approval
040 - Biogen faces another headwind with Zolgensma approval
Hi all, I'm back today talking about the approval of Avexis/Novartis' gene therapy for spinal muscular atrophy, Zolgensm... Read more
26 May 2019
•
34mins
Similar Podcasts
The Readout Loud
Biotech Bros
Biotech 2050 Podcast
Business Of Biotech
The Bio Report
The Long Run with Luke Timmerman
BioCentury This Week
Marketplace
Talking Biotech with Dr. Kevin Folta
Up First
Ranked #3
027 - Amarin Sells Off Amid Positive Vascepa Data
027 - Amarin Sells Off Amid Positive Vascepa Data
Amarin recently published data from their REDUCE-IT cardiovascular outcomes trial. Their EPA medicine, Vascepa, showed a... Read more
19 Nov 2018
•
22mins
Ranked #4
052 - BATTLING for the Top Anti-VEGF Eye Therapy
052 - BATTLING for the Top Anti-VEGF Eye Therapy
Happy Thanksgiving! In this video, I talk about all things related to eye diseases caused by over-proliferating endothel... Read more
29 Nov 2019
•
21mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Ranked #5
039 - Will Marker Therapeutics Succeed in Pancreatic Cancer?
039 - Will Marker Therapeutics Succeed in Pancreatic Cancer?
Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker Therapeutics' MultiTAA T Cell t... Read more
29 Apr 2019
•
21mins
Ranked #6
053 - Amarin Raises Guidance on Vascepa Label Expansion Approval. ASH Updates Impress.
053 - Amarin Raises Guidance on Vascepa Label Expansion Approval. ASH Updates Impress.
Amarin finally receives label expansion for Vascepa, which can now be marketed to patients with Triglyceride levels of g... Read more
18 Dec 2019
•
22mins
Ranked #7
055 - Cassava Sciences' NOVEL mechanism for Alzheimer's
055 - Cassava Sciences' NOVEL mechanism for Alzheimer's
Cassava Sciences is a neuroscience company with a focus on Alzheimer's disease. Their lead compound, PTI-125, is able to... Read more
12 Jan 2020
•
20mins
Ranked #8
051 - Amarin Receives UNANIMOUS Recommendation from Advisory Committee
051 - Amarin Receives UNANIMOUS Recommendation from Advisory Committee
I'm back! Here are the companies I touch on in this episode (recorded on Nov 14, 2019): Sarepta: 2:30Trevena: 4:08Viking... Read more
15 Nov 2019
•
22mins
Ranked #9
050 - Acasti Pharma's Novel Omega-3 Formulation Steps Up!
050 - Acasti Pharma's Novel Omega-3 Formulation Steps Up!
Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. ... Read more
20 Oct 2019
•
20mins
Ranked #10
054 - Exact Sciences' Cologuard NEEDS Greater Adoption to Justify Valuation
054 - Exact Sciences' Cologuard NEEDS Greater Adoption to Justify Valuation
Exact Sciences (EXAS) is a diagnostic company offering non-invasive colorectal cancer screening with their flagship prod... Read more
29 Dec 2019
•
24mins
Ranked #11
026 - Global Blood Therapeutics' Meager Approval Attempt
026 - Global Blood Therapeutics' Meager Approval Attempt
Today, I breakdown Sickle Cell Disease and Global Blood Therapeutics' Voxelotor. I write a more detailed article here: h... Read more
13 Nov 2018
•
12mins
Ranked #12
042 - Biotech M&As accelerate. IMMU's ADC shakes up breast cancer!
042 - Biotech M&As accelerate. IMMU's ADC shakes up breast cancer!
Today, I cover the latest in biotech with a highlight on Immunomedics and their antibody-drug conjugates for breast canc... Read more
27 Jun 2019
•
19mins
Ranked #13
037 - Sangamo Bounces Back! Viking's Backup Drug
037 - Sangamo Bounces Back! Viking's Backup Drug
In this video, I go through Sangamo's updated data with their Hemophilia A and Beta-Thalassemia treatments. I also talk ... Read more
10 Apr 2019
•
28mins
Ranked #14
032 - GILD Fails Phase 3 in NASH!
032 - GILD Fails Phase 3 in NASH!
On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treat... Read more
17 Feb 2019
•
17mins
Ranked #15
031 - Sangamo woes
031 - Sangamo woes
Today, I talk about Sangamo's updated data from their talks at the WORLDSymposium. We saw updates on their MPSI and MPSI... Read more
10 Feb 2019
•
27mins
Ranked #16
043 - Sarepta keeps the gene therapy throne in DMD! ContraVir submits NASH IND!
043 - Sarepta keeps the gene therapy throne in DMD! ContraVir submits NASH IND!
Hey everybody, hope you're all doing well! In this video, I talk about Pfizer's DMD gene therapy update that indicates c... Read more
14 Jul 2019
•
24mins
Ranked #17
035 - Trevena upside potential and more Amarin
035 - Trevena upside potential and more Amarin
Today I go through a trading idea for Trevena as well as the updated Amarin data. This is not investment advice. www.bre... Read more
22 Mar 2019
•
21mins
Ranked #18
041 - Is REGENXBIO a buy after Zolgensma approval?
041 - Is REGENXBIO a buy after Zolgensma approval?
Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important asset in early clinical t... Read more
11 Jun 2019
•
30mins
Ranked #19
048 - Advisory Committee votes YES on Aimmune's Palforzia
048 - Advisory Committee votes YES on Aimmune's Palforzia
In this video, I discuss the details of the advisory committee that recently occurred regarding Aimmune Therapeutics' pe... Read more
16 Sep 2019
•
24mins
Ranked #20
047 - Sarepta Receives CRL for Golodirsen! IOVA impresses in solid tumors.
047 - Sarepta Receives CRL for Golodirsen! IOVA impresses in solid tumors.
In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I also take a close look... Read more
2 Sep 2019
•
28mins
